Core Viewpoint - Yisheng Biotechnology (01061) has seen a significant stock increase, rising nearly 9% in the afternoon session, with a current price of HKD 4.36 and a trading volume of HKD 5.2576 million [1] Group 1: Product Development and Exhibition - The company will participate in the 2026 Asia-Pacific Academy of Ophthalmology (APAO 2026) conference from February 5 to 8 at the Hong Kong Convention and Exhibition Centre [1] - Yisheng Biotechnology will showcase two core products: EB12-20145P (Bevacizumab) and a single-dose Beifu Shuh eye drop, both of which are demonstrating strong clinical development momentum [1] - The EB12-20145P project has been selected for poster presentation at the conference, where clinical progress and research insights will be shared with the international ophthalmology community [1] Group 2: Strategic Partnerships - The company announced an exclusive distribution agreement between its wholly-owned subsidiary Majeton and Osteopore, a global leader in 3D-printed bioresorbable implants [1] - This collaboration marks a milestone for the company in the oral market and expands its product line in dental, orthodontic, and maxillofacial solutions [1] - The partnership is expected to support the company's pursuit of sustainable growth in the Chinese market [1]
亿胜生物科技午后涨近9% 公司将携多款核心眼科产品参展APAO 2026